Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Opinion | 'A Real-but-Vanilla Commercial Dispute': What We Heard This Week
32+ min ago (323+ words) — Quotable quotes heard by MedPage Today's reporters "The underlying case is a real-but-vanilla commercial dispute." -- Christopher Robertson, JD, PhD, of Boston University, discussing a medical software company's lawsuit against a former collaboratoropens in a new tab or window, who helped…...
FDA Approves Isembyld, First SMA Treatment To Target Muscle Loss
1+ hour, 22+ min ago (421+ words) A newly approved treatment for spinal muscular atrophy is moving toward U.S. availability, giving eligible children and adults an additional option to address muscle weakness. Scholar Rock announced September 11 that the Food and Drug Administration approved Isembyld, also known as apitegromab-mstn....
Weight-loss drugs shaping up to be a boon for grocers' pharmacy units
1+ hour, 9+ min ago (866+ words) By Ritika Dubey, The Canadian Press Posted September 13, 2026 6:00 am. While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it’s largely coming…...
Patients duped as fake pharmacies sell counterfeit weight-loss drugs
3+ hour, 27+ min ago (55+ words) The Times Patients duped as fake pharmacies sell counterfeit weight-loss drugs British regulators admit playing ‘whack-a-mole’ against organised criminals as thousands of illegal sellers use AI to push dangerous medication £1 for 3 months Enjoy unlimited access to all articles. Ends soon....
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial (SMMT:NASDAQ)
3+ hour, 9+ min ago (64+ words) Seeking Alpha nopparit/iStock via Getty Images Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in a late-stage lung cancer trial conducted by its partner Akeso (AKESF) in China. Ivonescimab reduced the risk…...
A $300,000 mansion and a lab for???their own???: State Medicines Service liquidated and new agency created
8+ hour, 52+ min ago (458+ words) A $300,000 mansion and a lab for “their own”: State Medicines Service liquidated and new agency created АНТИКОР - A $300,000 mansion and a lab for?their own?: State Medicines Service liquidated and new agency created This is reported by Glavcom. The previous…...
Health Headlines: Epidemics, Legal Battles, and Big Pharma Moves
7+ hour, 33+ min ago (985+ words) The Democratic Republic of Congo reports a surge in Ebola cases, now exceeding 7,000, with the outbreak spreading to a seventh province, South Ubangi. Government data highlights the expanding crisis. In the U.S., authorities declared the end of a significant cyclosporiasis outbreak…...
Health Headlines: Epidemics, Legal Battles, and Big Pharma Moves | Health
7+ hour, 33+ min ago (205+ words) Health Headlines: Epidemics, Legal Battles, and Big Pharma Moves Devdiscourse Health Headlines: Epidemics, Legal Battles, and Big Pharma Moves The Democratic Republic of Congo sees Ebola cases surpass 7,000. The U.S. ends its largest cyclosporiasis outbreak, while Bayer faces a court test…...
A billion-dollar drug was found in Easter Island soil – what scientists and companies owe the Indigenous people they studied
2+ hour, 17+ min ago (295+ words) Cancer. Diabetes. Aging itself. Rapamycin’s potential to treat an array of diseases has been a source of scientific fascination. But many aren’t aware of its origins – and its complicated legacy....
The week in pharma: action, reaction and insight – week to September 11, 2026
7+ hour, 25+ min ago (323+ words) Last week’s regulatory news saw the US Food and Drug Administration (FDA) grant accelerated approval for AstraZeneca’s Etcamah combination for the treatment of breast cancer. On the research front, Novartis suffered another setback, this time with its Phase III trial…...